DermTech International, Inc., a biotechnology company dedicated to bringing genomic medicine to dermatologists, announces that their discovery data on its new genomic assay for melanoma has been published in the British Journal of Dermatology. The test is based on the EGIR™ technology (Epidermal Genetic Information Retrieval) that non-invasively collects cells from the skin's surface using a custom adhesive. Details from the paper titled, "Non-invasive Genomic Detection of Melanoma" show that the test is 100 percent sensitive in identifying melanoma.